Advances in Hematology

Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma


Publishing date
08 Jun 2012
Status
Published
Submission deadline
13 Jan 2012

1Medical Genetics Unit, University of Perugia, S. Andrea delle Fratte, Perugia, Italy

2Dipartimento di Ematologia, Azienda Ospedaliero-Universitaria San Giovanni Battista di Torino, Torino, Italy

3Divisione di Ematologia, Azienda Ospedaliero-Universitaria San Giovanni Battista di Torino, Via Genova 3, Torino, Italy

4Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Pad. Marcora, via F. Sforza 35, 20122, Milano, Italy


Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma

Description

Immunomodulating agents (ImiDs) are a novel class of anticancer drugs that have demonstrated impressive antitumor activity in various malignant disorders. Of this class, most recent research has been focused on the remarkably active agent, lenalidomide. Lenalidomide was designed to enhance immunologic and anticancer properties while potentially decreasing neurotoxic and teratogenic adverse effects of the parent compound thalidomide.

The introduction of this novel agent has broadened the therapeutic landscape of hematologic malignant disorders including Multiple Myeloma (MM) and, more recently, other B-cell neoplasms.

In this issue, we will focus on mechanisms of action and results from clinical investigation that report the relevance of lenalidomide for the treatment of B-cell disorders including MM, Chronic Lymphocytic Leukaemia (CLL), and Non-Hodgkin's lymphomas by offering new mechanisms for targeting these diseases.

In particular, manuscripts defining the role of lenalidomide as part of the induction therapy before Hematopoietic Stem Cells Transplantation (HSCT) as well as its use as extended maintenance therapy post-HSTC in patients with MM will be of great interest.

Moreover, we will welcome papers emphasizing the efficacy of lenalidomide used alone or in combination with other agents for the chemotherapy of Mantle cell and low-grade lymphomas as well as in association with chemoimmunotherapy as a therapeutic strategy in patients with diffuse large B-cell lymphomas.

Finally, manuscripts regarding clinical safety and/either efficacy of the use of lenalidomide as single agent or as in combination with conventional or biological drugs in patients with CLL will be acknowledged. Potential topics include, but are not limited to:

  • Lenalidomide: mechanism of action
  • Lenalidomide as part of the induction therapy before HSCT and its use as consolidation and maintenance therapy of multiple myeloma
  • Lenalidomide in chronic lymphocytic leukaemia
  • Lenalidomide in diffuse large B-cell lymphoma
  • Lenalidomide in Mantle cell and low-grade Non-Hodgkin's lymphomas

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ah/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2013
  • - Article ID 812605
  • - Editorial

Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma

Anna Marina Liberati | Umberto Vitolo | ... | Agostino Cortelezzi
  • Special Issue
  • - Volume 2012
  • - Article ID 861060
  • - Review Article

Lenalidomide in Diffuse Large B-Cell Lymphoma

Catherine Thieblemont | Marie-Hélène Delfau-Larue | Bertrand Coiffier
  • Special Issue
  • - Volume 2012
  • - Article ID 621958
  • - Review Article

Practical Approaches to the Use of Lenalidomide in Multiple Myeloma: A Canadian Consensus

Donna Reece | C. Tom Kouroukis | ... | John Ashkenas
  • Special Issue
  • - Volume 2012
  • - Article ID 842945
  • - Review Article

Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma

Roberta Martiniani | Valentina Di Loreto | ... | Anna Marina Liberati
  • Special Issue
  • - Volume 2012
  • - Article ID 513702
  • - Review Article

Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies

Jessica M. McDaniel | Javier Pinilla-Ibarz | P. K. Epling-Burnette
  • Special Issue
  • - Volume 2012
  • - Article ID 801495
  • - Review Article

Secondary Primary Malignancies in Multiple Myeloma: An Old Nemesis Revisited

Jay Yang | Howard R. Terebelo | Jeffrey A. Zonder
  • Special Issue
  • - Volume 2012
  • - Article ID 906247
  • - Review Article

Lenalidomide in the Treatment of Young Patients with Multiple Myeloma: From Induction to Consolidation/Maintenance Therapy

Barbara Lupo | Antonio Palumbo
  • Special Issue
  • - Volume 2012
  • - Article ID 393864
  • - Review Article

Lenalidomide in the Treatment of Chronic Lymphocytic Leukemia

Agostino Cortelezzi | Mariarita Sciumè | Gianluigi Reda
  • Special Issue
  • - Volume 2012
  • - Article ID 498342
  • - Review Article

Lenalidomide in Diffuse Large B-Cell Lymphomas

Annalisa Chiappella | Umberto Vitolo
  • Special Issue
  • - Volume 2012
  • - Article ID 523842
  • - Review Article

Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas

Marco Gunnellini | Lorenzo Falchi
Advances in Hematology
 Journal metrics
Acceptance rate8%
Submission to final decision77 days
Acceptance to publication25 days
CiteScore1.600
Journal Citation Indicator-
Impact Factor-
 Submit

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.